Valuation: Plasmatech Biopharmaceuticals Inc

Market Cap 366M 318M 297M 272M 514M 34.88B 523M 3.49B 1.37B 17.39B 1.37B 1.34B 57.59B P/E 2026 *
-8.69x
P/E 2027 * -91.7x
Enterprise Value 366M 318M 297M 272M 514M 34.88B 523M 3.49B 1.37B 17.39B 1.37B 1.34B 57.59B EV / Sales 2026 *
5.59x
EV / Sales 2027 * 2.71x
Free-Float
79.49%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Plasmatech Biopharmaceuticals Inc

Manager TitleAgeSince
Chief Executive Officer 50 14/10/2021
Director of Finance/CFO 42 13/03/2022
Chief Tech/Sci/R&D Officer - 19/10/2025
Director TitleAgeSince
Director/Board Member 58 28/02/2006
Director/Board Member 64 24/03/2021
Director/Board Member 63 18/04/2021
Change 5-day change 1-year change 3-year change Capi.($)
-0.44%+15.74%+35.85%+3.70% 76.15B
-0.67%-10.00%+19.77%+174.96% 48.89B
-4.18%+42.30%+42.30%+42.30% 47.83B
+1.01%+8.83%-52.93%-53.63% 41.37B
-0.56%-0.18%+52.95%-25.68% 29.99B
-0.91%+0.65%+56.67%+80.31% 24.23B
+0.58%+1.98%+99.75%-49.97% 21.89B
-0.81%-4.39%-7.53%+165.02% 19.25B
-7.35%-4.68%+64.90%+111.65% 17.14B
Average -1.48%+1.01%+34.64%+49.85% 36.3B
Weighted average by Cap. -1.20%+2.36%+29.51%+42.27%

Financials

2026 *2027 *
Net sales 65.51M 56.93M 53.09M 48.79M 92.02M 6.24B 93.62M 626M 245M 3.11B 246M 241M 10.31B 135M 117M 109M 100M 190M 12.86B 193M 1.29B 505M 6.41B 507M 496M 21.24B
Net income -42.25M -36.72M -34.24M -31.47M -59.36M -4.03B -60.39M -404M -158M -2.01B -159M -155M -6.65B -2.1M -1.83M -1.7M -1.56M -2.95M -200M -3M -20.07M -7.86M -99.86M -7.89M -7.72M -331M
Net Debt - -
Logo Plasmatech Biopharmaceuticals Inc
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-